Lexicon Pharmaceuticals announced positive top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS).  Results from this Phase 2 study showed a significant improvement in IBS symptoms.  These results will be presented at GASTRO 2009, a joint world conference in the area of gastroenterology, on November 25, 2009.  

LX1031 is an orally available, locally acting inhibitor of tryptophan hydroxylase (TPH), an enzyme necessary for the biosynthesis of serotonin. LX1031 acts by selectively decreasing the production of serotonin in the gastrointestinal tract.

For more information call (281) 863-3000 or visit www.lexpharma.com.